Catherine is hopeful that the success of George in using the new treatment, trametinib, will lead to its wider availability on the NHS.
LCH is a rare condition that affects approximately 50 children in the UK every year.
In the case of George, cells that typically protect the skin have migrated to other organs, including his liver, bone, and spleen.
Catherine described the initial diagnosis of her son as “terrifying”.
At around 18 months old, George developed a skin rash, and by his second birthday, he frequently experienced fatigue and severe abdominal pain.
Following several tests, he was diagnosed with LCH and underwent 12 months of chemotherapy.
Catherine is hopeful that the success of George in using the new treatment, trametinib, will lead to its wider availability on the National Health Service (NHS). Langerhans cell histiocytosis (LCH) is a rare condition that affects approximately 50 children in the UK each year. In George’s case, the condition has caused cells that usually protect the skin to migrate to his liver, bone, and spleen.
Catherine expressed her initial diagnosis of her son as “terrifying”. George developed a skin rash at around 18 months old, and by his second birthday, he frequently experienced fatigue and severe abdominal pain. After undergoing several tests, he was diagnosed with LCH and received 12 months of chemotherapy.
Now, Catherine is hopeful that George’s success with trametinib will increase its availability on the NHS. Trametinib is a new treatment that has shown positive results in George’s case. By sharing his story and advocating for the availability of this treatment, Catherine aims to improve access to it for other children with LCH.
LCH is a challenging condition that requires effective and accessible treatments. Currently, the availability of trametinib on the NHS is limited. Catherine believes that if more children like George can benefit from this treatment, it would significantly improve their quality of life and long-term outcomes.
The success of trametinib in George’s case highlights the importance of continued research and development of treatments for rare conditions like LCH. Catherine’s hope is that by raising awareness and advocating for increased availability of trametinib, more children with LCH will have access to this potentially life-changing treatment option.
In conclusion, Catherine’s hope for George’s success with trametinib to increase its availability on the NHS reflects the need for improved treatment options for children with LCH. By sharing George’s story and advocating for better access to trametinib, Catherine aims to make a positive impact on the lives of other children with this rare condition.